Real-World Effects of Finerenone in Diabetic Kidney Disease: Data from Turkish Multicenter Cohort (FINE-TURK Study)

Le résumé fourni par la source

Background: This study aimed to evaluate the renal outcomes associated with finerenone use in a Turkish diabetic chronic kidney disease (CKD) cohort. Methods: This study demonstrated initial and first month data of adult participants with diabetic CKD who received finerenone in 34 nephrology units in Turkey between February 2024 to April 2025. Key outcomes included changes in estimated glomerular filtration rate (eGFR), urinary albumin-creatinine ratio (UACR), serum potassium levels, and adverse events. Results: A total of 366 participants were included. Baseline eGFR was 58.24±25.68 mL/min/1.73m2 and median UACR was 1586 mg/g. The mean level of serum potassium was 4.54±0.72 mmol/L. All participants were receiving renin-angiotensin system (RAS) inhibitors, and 94% were concurrently treated with an SGLT2 inhibitor. Forty one % reduction in albuminuria was observed at 1 month following using finerenone. After 1 month using of finerenone, 12 of 366 (3.27%) participants showed hyperpotassemia (>5.5 mmol/L). Eight of 12 hyperpotassemic participants, complication was managed by adding calcium polystyrene sulfonate; while in the remaining 4 patients, finerenone was temporarily discontinued. Conclusion: This real-world multi-center cohort preliminary data suggests that finerenone is effective and well tolerated in diabetic CKD in Turkish population. Ongoing surveillance and further real-world evidence studies will be crucial to optimize diabetic chronic kidney disease treatment regimens in diverse populations. Real-World Preliminary Data of FINE-TURK Study - Parameter Real-World Data of FINE-TURK Study (n=366) FIDELITY Study (n=13.026) Comment Mean age (years) 60.40 ± 09.60 ~64 Slightly younger population. Male/Female (%) 64% / 36% 69% / 31% Higher proportion of females in the real-world setting Baseline eGFR (mL/min/1.73 m2) 58.24 ± 25.98 57.60 ± 16.70 Comparable baseline kidney function Baseline Urinary Albumin Creatinine Ratio (mg/g) Median: 1584 Median: 515 More advanced albuminuria in the real-world cohort. HbA1c (%) 8.24 ± 2.40 7.70 ± 3.10 Worse glycemic control in the real-world population Systolic Blood Pressure (mmHg) 137.87 ± 20.03 136.7 ± 18.30 Comparable Diastolic Blood Pressure (mmHg) 82.86 ± 11.60 76.60 ± 09.24 Higher in the real-world cohort Serum Potassium (mmol/L) 4.54 ± 0.68 4.40 ± 0.54 Comparable eGFR at 1 month (mL/min/1.73 m2) 52.86 ± 23.80 none NA Decrease in Albuminuria (%) 41.7% ~31.6% Significant reduction observed; different measurement methods. Rate of Hyperpotassemia (%) (Potassium >5.5 mmol/L) 3.27% 14.0% Lower hyperpotassemia incidence in the real-world cohort(Could be according to high percent of SGLT2 usage) Deaths due to Hyperpotassemia and/or Other Side Effects of Finerenone None Not specifically reported Positive safety profile Gynecomastia None Not reported Not an expected side effect Severe Hypotension(Blood Pressure<90/50 mmHg) None Low incidence Well-tolerated in the real-world cohort

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.